Showing results (261-270 of 401) with videos related to

Sort By:
Pageof 41
JCO Oncology Practice|August 13, 2024
Effects of Adjuvant Endocrine Therapy-Specific Perceptions on Response to a Behavioral Intervention for Adjuvant Endocrine Therapy Adherence in Patients With Breast CancerKelcie D Willis, Emily A Walsh, Laura E Dunderdale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2015
Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment FactorsErica T Warner, Rulla M Tamimi, Melissa E Hughes, et al.
JNCI Cancer Spectrum|May 13, 2021
Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance)Jennifer A Ligibel, Luke Huebner, Hope S Rugo, et al.
The Oncologist|May 20, 2023
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and ControversiesStefania Morganti, Brittany L Bychkovsky, Philip D Poorvu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2016
Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer SurvivalAnn H Partridge, Melissa E Hughes, Erica T Warner, et al.
Breast Cancer Research and Treatment|June 8, 2026
Age-related differences in psychological distress and persistent postsurgical pain after surgery for management of non-invasive breast lesionsJenna M Wilson, Shoshana M Rosenberg, Kerri-Anne Crowell, et al.
Breast Cancer Research and Treatment|October 27, 2012
Time to diagnosis and breast cancer stage by race/ethnicityErica T Warner, Rulla M Tamimi, Melissa E Hughes, et al.
Breast Cancer Research : BCR|February 5, 2020
ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosisAdi Zundelevich, Maya Dadiani, Smadar Kahana-Edwin, et al.
Breast Cancer Research : BCR|March 14, 2020
Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosisAdi Zundelevich, Maya Dadiani, Smadar Kahana-Edwin, et al.
Future Oncology (London, England)|June 26, 2024
OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancerSara M Tolaney, Angela DeMichele, Toshimi Takano, et al.
Pageof 41